Actuate Therapeutics IncACTU
ASignal's systematic analysis rates ACTU as Neutral.
Reflects the latest available analysis · analyzed Aug 20, 2026
The case on ACTU
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Positive MACD histogram indicating strengthening momentum
- Price near lower Bollinger Band suggesting potential reversal
- No debt on balance sheet (total_debt: $0)
- Cash-rich position with $4.43M in total cash
- Negative operating and free cash flow (-$19.84M and -$12.47M respectively)
- Negative return on assets (-213.40%)
- All margin metrics at 0.00%, indicating no profitability
- Forward P/E of -1.70x suggests unprofitable outlook
- Market cap under $30M indicating high risk
- No Reddit mentions, low retail sentiment visibility
See the full verdict on ACTU
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ACTU
Most investors never get a second opinion, let alone several. ASignal runs ACTU past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.